

## **Risk of ischemic stroke and total cerebrovascular disease in familial hypercholesterolemia; a register study from Norway**

### **Cover title: Stroke in familial hypercholesterolemia**

Anders Hovland MD, PhD<sup>1,2</sup>, Liv J. Mundal MD, PhD<sup>3</sup>, Jannicke Igland PhD<sup>4,5</sup>, Marit B. Veierød PhD<sup>7</sup>, Kirsten B. Holven PhD<sup>6,8</sup>, Martin Prøven Bogsrud MD, PhD<sup>8</sup>, Grethe S. Tell MPH, PhD<sup>5,9</sup>, Trond P. Leren MD, PhD<sup>10</sup>, Kjetil Retterstøl MD, PhD<sup>3,6</sup>

<sup>1</sup>Division of Internal Medicine, Nordland Hospital, Bodø, Norway, <sup>2</sup>Department of Clinical Medicine, University of Tromsø, Tromsø, Norway, <sup>3</sup>The Lipid Clinic, Oslo University Hospital Rikshospitalet, Oslo, Norway, <sup>4</sup>Department of Health and Social Science, Centre for Evidence-Based Practice, Western Norway University of Applied Science, Bergen, Norway, <sup>5</sup>Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway, <sup>6</sup>Department of Nutrition, University of Oslo, Oslo, Norway, <sup>7</sup>Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, University of Oslo, Oslo, Norway, <sup>8</sup>National Advisory Unit on Familial Hypercholesterolemia, Oslo University Hospital, Oslo, Norway, <sup>9</sup>Division of Mental and Physical Health, Norwegian Institute of Public Health, Bergen, Norway, <sup>10</sup>Unit for Cardiac and Cardiovascular Genetics, Oslo University Hospital Ullevål, Oslo, Norway.

#### **Corresponding author:**

Anders Hovland

Division of Internal Medicine

Nordland Hospital

N-8092 Bodø

Telephone: +4775534000

E-mail : [anders.w.hovland@gmail.com](mailto:anders.w.hovland@gmail.com)

**Keywords:** Familial hypercholesterolemia; stroke; cerebrovascular disease; LDL-cholesterol

**Subject terms:** Lipids and cholesterol; Risk Factors; Cerebrovascular Disease/Stroke; Ischemic Stroke

## **Abstract**

### ***Background and purpose***

Familial hypercholesterolemia (FH) is a common autosomal dominant disease leading to increased level of serum low-density lipoprotein cholesterol and risk of coronary heart disease (CHD). Whether FH increases the risk of cerebrovascular disease including ischemic stroke is debated. Accordingly we studied the incidence of cerebrovascular disease in a cohort of persons with genetically verified FH compared to the entire Norwegian population, and examined whether persons in this cohort with previous cohort had increased risk of cerebrovascular disease.

### ***Methods***

Incidence rates of hospitalization for cerebrovascular disease (among 3144 persons with FH) and ischemic stroke (among 3166 persons with FH) were estimated by linkage of FH persons to CVDNOR; a nationwide database of cardiovascular disease hospitalizations (2001-2009). We calculated standardized incidence ratios (SIRs), and used Cox regression to estimate hazard ratios (HRs).

### ***Results***

A total of 46 cases (19 women and 27 men) of cerebrovascular disease were observed in the cohort of persons with FH, with no increased risk of cerebrovascular disease compared to the general population (SIR=1.0, 95% confidence interval (CI) (0.8-1.4)). Total number of ischemic strokes in the cohort of persons with FH was 26 (9 women and 17 men), with no increased risk compared to the general population (SIR=1.0, 95%CI (0.7-1.5)). Prior CHD significantly increased cerebrovascular disease risk in women (HR=3.29, 95%CI 1.20-9.00) but not in men (HR=1.03, 95%CI (0.45-2.37);  $p_{\text{interaction}}=0.04$ ).

### ***Conclusions***

In a large cohort of genetically verified FH, risks of cerebrovascular disease and ischemic stroke were not increased compared to the total Norwegian population.

## **Introduction**

Stroke is an important cause of disability and death worldwide,<sup>1</sup> and there are several risk factors for stroke such as hypertension, carotid artery atherosclerosis and smoking.<sup>2</sup> Atherosclerosis is an underlying factor for stroke, and accordingly, low-density lipoprotein (LDL)-cholesterol lowering therapy is important in both primary and secondary prevention of cerebrovascular diseases including stroke.<sup>3</sup>

Persons with heterozygous familial hypercholesterolemia (FH) have increased levels of LDL-cholesterol from birth,<sup>4</sup> and increased risk of premature coronary heart disease (CHD) and heart failure due to the increased LDL-cholesterol load.<sup>5-7</sup> With the increased risk of atherosclerosis, the risk of stroke in FH patients is expected to be high. However, whether the risk of stroke in FH patients is increased has been debated and previous studies have yielded inconsistent results.<sup>8,9</sup>

Our aim was to investigate risk of cerebrovascular disease including ischemic stroke in a genetically verified cohort of persons with FH in comparison with the risk in the entire Norwegian population. In addition, we aimed to examine whether previous hospitalization for CHD was associated with the risk of cerebrovascular disease, including ischemic strokes.

## **Material and methods**

The study was approved by the Regional Committee for Medical and Health Research Ethics, South-East Norway, and is a cohort study of persons with FH identified from the Unit for Cardiac and Cardiovascular Genetics (UCCG) Registry linked to the Norwegian Cause of Death Registry and the Cardiovascular Disease in Norway (CVDNOR) project database. Data used in this project cannot be made available for researchers without new approvals because of data protection legislation in Norway. All patients with genetically diagnosed FH in Norway are included in the National UCCG Registry after written informed consent. Prior to the registry linkage all patients received a letter and were offered to be removed from the list and not participate in the registry linkage.

An incident event of cerebrovascular disease was defined as a hospitalization with cerebrovascular disease as main or secondary diagnosis or death with cerebrovascular disease as the underlying cause, without any prior hospitalizations with cerebrovascular disease during the past seven years. Patients were followed from inclusion in the FH registry until the first occurrence of cerebrovascular disease, death or 31st December 2009, whichever came first. Incident events of ischemic stroke were defined in the same manner.

We calculated incidence rates and standardized incidence ratios (SIRs with 95% confidence intervals (CIs)) for cerebrovascular disease and ischemic stroke using incidence rates for the total Norwegian population as reference rates. The association between CHD and risk of cerebrovascular disease was analyzed by including CHD as

a time-dependent covariate in a Cox regression, reported as hazard ratios (HRs) with 95% CIs. Further details are provided in Methods in the online-only data supplement.

## Results

In total, 3144 persons with FH (46.6% men, mean (standard deviation (SD)) age at inclusion was 39.9 years (14.9)) were included in analyses of cerebrovascular disease and compared to the age, sex and calendar year adjusted Norwegian population. The analyses of ischemic stroke included 3166 persons with FH (46.5% men, mean (SD) age at inclusion 39.2 years (14.3)). Total follow-up was more than 18 500 person years.

A total of 46 cases of cerebrovascular disease were observed in persons with FH, 19 women and 27 men, and no significant increased risk of cerebrovascular disease was found (Table 1). When ischemic strokes were analyzed, 26 ischemic strokes were observed (9 women and 17 men), and again, no significant increased risk in persons with FH (Table 1).

In the group of 46 patients with cerebrovascular disease, 23 (50%) had previous CHD, 11 women (57.9%) and 12 men (44.4%). In Cox regression analyses of the association between CHD and cerebrovascular disease we found a significant interaction between sex and CHD ( $p_{\text{interaction}}=0.04$ ). In separate analyses for men and women, a significant association between previous CHD and risk of cerebrovascular disease was found in women (HR=3.29, 95% CI (1.20-9.00)) but not in men (HR=1.03, 95% CI (0.45-2.37)).



## **Discussion**

In our cohort of 3170 genetically verified persons with FH and more than 18 500 person-years of follow-up, there was no increased incidence of cerebrovascular disease or ischemic stroke compared to the entire population of Norway, and as far as we know, this is the largest data set to date investigating this. Acknowledging the contribution of age to the risk of cerebrovascular disease, mean age at inclusion was relatively low in the our cohort.

The finding of no increased risk of cerebrovascular disease and ischemic stroke in persons with high LDL-cholesterol from birth is interesting, and challenges the concept of LDL-cholesterol being a major risk factor for cerebrovascular disease and ischemic stroke. Importantly, in the present cohort, the risk of CHD was more than fourfold increased during the same period of time.<sup>6</sup> A Mendelian randomization study recently found that persons with lifelong low levels of PCSK9 and LDL-cholesterol had lower risk of CHD, but with no effect on ischemic stroke.<sup>10</sup> This has questioned the relation between LDL-cholesterol and ischemic strokes. Indeed, much of the support for the LDL-cholesterol hypothesis regarding risk of ischemic stroke is based upon the reduced incidence of stroke found in landmark statin trials.<sup>11</sup> However, the largest published meta-analysis of statin trials found only a small reduction in stroke risk among statin-treated men, and no effect on stroke incidence in women.<sup>11</sup>

The results of most previous studies on cerebrovascular disease and stroke in persons with FH are in agreement of our findings.<sup>9,12,13</sup> In contrast, Toell et al recently demonstrated increased prevalence of ischemic strokes and transient ischemic attacks in persons with FH,<sup>8</sup> however, with FH defined by clinical criteria and not genetic criteria.

Previous hospitalization for CHD increased the risk of cerebrovascular disease in women in the present study but surprisingly not in men, this finding warrants further investigation as the sample is quite small.

### **Limitations**

Registration of actual lipid levels and medication, was not possible in the present study, and should be addressed in future studies of stroke in persons with FH. Given the registry-based study design, we did not have information on lifestyle factors. Selection bias is always an important issue in register studies. Importantly, all physicians in Norway may request genetic testing of FH free of charge, reducing the risk of bias due to economy.

### **Conclusions**

In this large cohort of 3170 genetically verified persons with FH, with more than 18 500 person-years of follow-up, risks of cerebrovascular disease and ischemic stroke were not increased compared to the age, sex and calendar year adjusted Norwegian population, despite the previously reported higher risk of CHD in this cohort. Our results raise new questions regarding the specific role of LDL-cholesterol in cerebrovascular disease and ischemic stroke.

## **Acknowledgements**

The authors thank Tomislav Dimoski, The Norwegian Institute of Public Health, Oslo, Norway, for his contribution by developing the software necessary for obtaining data, conducting the data collection and quality assurance of the data.

## **Sources of funding**

University of Oslo, Oslo, Norway, The Throne-Holst Foundation, Oslo, Norway, and by the South-Eastern Norway Regional Health Authority, Oslo, Norway

## **Disclosures**

Dr. Holven has received research grants and/or personal fees from Mills AS, TINE BA, Olympic Seafood, Kaneka, Amgen, Sanofi, and Pronova, outside the submitted work.

Dr Prøven Bogsrud reports grants and/or personal fees from Amgen, Sanofi, MSD, Boehringer Ingelheim, Mills DA and Kaneka, outside the submitted work.

Dr. Retterstøl reports grants and/or personal fees from Amgen, Bayer, Mills DA, Norwegian Directorate of Health, Norwegian Medical Association, MSD (Norway), Sanofi, Sunivon, Takeda, Oslo Economics and Mills DA Heart foundation, outside the submitted work. The other authors report no conflicts.

## References

1. GBD NDCG. Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet Neurol.* 2017;16:877-897.
2. Hankey GJ. Stroke. *Lancet.* 2017;389:641-654.
3. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. *Eur Heart J.* 2016;37:2999-3058.
4. Defesche JC, Gidding SS, Harada-Shiba M, Hegele RA, Santos RD, Wierzbicki AS. Familial hypercholesterolaemia. *Nat Rev Dis Primers.* 2017;3:17093.
5. Hovland A, Mundal LJ, Igland J, Veierød MB, Holven KB, Bogsrud MP et al. Increased risk of heart failure and atrial fibrillation in heterozygous familial hypercholesterolemia. *Atherosclerosis.* 2017;266:69-73.
6. Mundal LJ, Igland J, Veierød MB, Holven KB, Ose L, Selmer RM et al. Impact of age on excess risk of coronary heart disease in patients with familial hypercholesterolaemia. *Heart.* 2018;104:1600-1607.
7. Nordestgaard BG, Cosentino F, Landmesser U, Laufs U. The year in cardiology 2017: prevention. *Eur Heart J.* 2018;39:345-353.
8. Toell T, Mayer L, Pechlaner R, Krebs S, Willeit K, Lang C et al. Familial hypercholesterolaemia in patients with ischemic stroke or transient ischemic attack. *Eur J Neurol.* 2018;25:260-267.
9. Beheshti S, Madsen CM, Varbo A, Benn M, Nordestgaard BG. Relationship of Familial Hypercholesterolemia and High LDL Cholesterol to Ischemic Stroke: The Copenhagen General Population Study. *Circulation.* 2018;138:578-589.
10. Hopewell JC, Malik R, Valdés-Márquez E, Worrall BB, Collins R, METASTROKE Collaboration of the ISGC. Differential effects of PCSK9 variants on risk of coronary disease and ischaemic stroke. *Eur Heart J.* 2018;39:354-359.
11. Cholesterol TTCTTC, Fulcher J, O'Connell R, Voysey M, Emberson J, Blackwell L et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. *Lancet.* 2015;385:1397-1405.

12. Huxley RR, Hawkins MH, Humphries SE, Karpe F, Neil HAW, Meschia JF. Risk of Fatal Stroke in Patients With Treated Familial Hypercholesterolemia: A Prospective Registry Study \* Editorial Comment. *Stroke*. 2003;34:22-25.
13. Kjærgaard KA, Christiansen MK, Schmidt M, Olsen MS, Jensen HK. Long-Term Cardiovascular Risk in Heterozygous Familial Hypercholesterolemia Relatives Identified by Cascade Screening. *J Am Heart Assoc*. 2017;6:e005435.

Table 1. Standardized incidence ratios (SIRs) for cerebrovascular disease and ischemic strokes in persons with familial hypercholesterolemia.

<b>Disease</b>	<b>Gender</b>	<b>Incident cases</b>	<b>Person years in 1000</b>	<b>Crude incidence rate per 1000 person years (95% CI)</b>	<b>Expected number of cases</b>	<b>SIR (95% CI)*</b>
<b>Cerebrovascular disease (N=3144)</b>						
	Women	19	9.7	2.0 (1.2-3.1)	21.6	0.9 (0.6-1.4)
	Men	27	8.5	3.2 (2.2-4.6)	23.2	1.2 (0.8-1.7)
	Total	46	18.3	2.5 (1.9-3.4)	44.8	1.0 (0.8-1.4)
<b>Ischemic stroke (N=3166)</b>						
	Women	9	9.8	0.9 (0.5-1.8)	12.1	0.8 (0.4-1.5)
	Men	17	8.6	2.0 (1.2-3.2)	13.6	1.3 (0.8-2.1)
	Total	26	18.4	1.4 (1.0-2.1)	25.1	1.0 (0.7-1.5)

\* SIR=Standardized incidence ratio obtained using indirect standardization. CI=Confidence interval.